SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
Open Access
- 1 September 2021
- journal article
- review article
- Published by Elsevier in Revista Portuguesa de Cardiologia (English Edition)
- Vol. 40 (9) , 687-693
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art reviewDiabetologia, 2018
- The effect of dapagliflozin treatment on epicardial adipose tissue volumeCardiovascular Diabetology, 2018
- SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trialCardiovascular Diabetology, 2018
- Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesisDiabetes, Obesity and Metabolism, 2017
- Sodium Glucose Cotransporter-2 Inhibition in Heart FailureCirculation, 2017
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart FailureJAMA Cardiology, 2017
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart FailureEuropean Journal of Heart Failure, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Biology of Human Sodium Glucose TransportersPhysiological Reviews, 2011